European Registry of Next Generation Imaging in Advanced Prostate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorFundacio Puigvert
About this trial
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging.
Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form.
Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.
Eligibility criteria
Qualifiers
Adult male patients (≥18 years with no upper age limit).
Histologically proven prostate cancer.
Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
Patients who authorize their participation in the study by signing a written informed consent form (ICF).
Disqualifiers
Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
Patients who will not be able to complete the study.
Trial design
Treatments tested in this trial
- Imaging
Treatment groups
600 Participants
are divided into 3 treatment groupsSponsors and collaborators
Fundacio Puigvert
Lead sponsor
European Association of Urology Research Foundation
Collaborator
GUARD Consortium (Genitourinary Alliance for Research and Development)
Collaborator
European Association of Urology - Section of Urological Imaging
Collaborator
Johnson & Johnson
Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborator
Source ClinicalTrials.gov